DMTr-LNA-5MeC(Bz)-3′-CED-phosphoramidite (CAS: 206055-82-5) is a powerful reagent for LNA oligonucleotide synthesis. The LNA modification boosts binding affinity and stability, while the 5-methylcytosine (5MeC) enhances hybridization strength. The benzoyl (Bz) group protects the cytosine during synthesis, and the DMTr group allows easy monitoring throughout the process.
Key Features:
- LNA Modification: Strengthens binding affinity and increases oligonucleotide stability.
- 5-Methylcytosine (5MeC): Further improves hybridization, ensuring stronger binding to target sequences.
- Benzoyl (Bz) Protection: Shields cytosine during synthesis for clean and efficient production.
- DMTr Group: Enables easy monitoring and purification, simplifying the synthesis process.
Applications:
- Oligonucleotide Synthesis: Ideal for synthesizing LNA-modified oligonucleotides with high stability and enhanced binding.
- Therapeutics: Perfect for developing antisense oligonucleotides and RNA-based therapies due to its resistance to degradation.
- Diagnostic Probes: Useful in creating high-affinity probes for molecular diagnostics and assays.
Benefits:
- Increased Stability: LNA modification provides strong resistance to enzymatic degradation, extending the lifespan of oligonucleotides in biological systems.
- Stronger Hybridization: The 5MeC addition ensures better hybridization, delivering more accurate binding with target sequences.
- Efficient Synthesis: The DMTr group simplifies tracking and purification, resulting in high-quality oligonucleotides.
DMTr-LNA-5MeC(Bz)-3′-CED-phosphoramidite (CAS: 206055-82-5) enhances stability, binding strength, and synthesis efficiency, making it perfect for research, diagnostics, and therapeutic development.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
